NDAINJECTIONINJECTABLE
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORGARAN (danaparoid sodium) is an injectable anticoagulant approved in 1996 for prevention of thromboembolic complications. It is a low-molecular-weight heparinoid that inhibits thrombin generation through Factor Xa and thrombin inhibition. The drug is typically used in patients with heparin-induced thrombocytopenia (HIT) or those requiring anticoagulation who cannot tolerate heparin.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely focused on lifecycle extension or managed transition strategies rather than aggressive growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORGARAN currently shows zero linked job postings, reflecting its late-lifecycle stage and niche market position. Professionals joining this product should anticipate limited growth opportunity and focus on retention in a specialized, stable segment rather than career acceleration.
Brand ManagerMedical Science Liaison (MSL)
Worked on ORGARAN at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.